BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25242043)

  • 1. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
    Schneider RK; Ademà V; Heckl D; Järås M; Mallo M; Lord AM; Chu LP; McConkey ME; Kramann R; Mullally A; Bejar R; Solé F; Ebert BL
    Cancer Cell; 2014 Oct; 26(4):509-20. PubMed ID: 25242043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
    Bello E; Pellagatti A; Shaw J; Mecucci C; Kušec R; Killick S; Giagounidis A; Raynaud S; Calasanz MJ; Fenaux P; Boultwood J
    Br J Haematol; 2015 Oct; 171(2):210-214. PubMed ID: 26085061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
    Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
    Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.
    Stalmann USA; Ticconi F; Snoeren IAM; Li R; Gleitz HFE; Cowley GS; McConkey ME; Wong AB; Schmitz S; Fuchs SNR; Sood S; Leimkühler NB; Martinez-Høyer S; Banjanin B; Root D; Brümmendorf TH; Pearce JE; Schuppert A; Bindels EMJ; Essers MA; Heckl D; Stiehl T; Costa IG; Ebert BL; Schneider RK
    Blood Adv; 2022 Mar; 6(6):1780-1796. PubMed ID: 35016204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
    Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
    EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
    Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL
    Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
    Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
    Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
    Lee JH; List A; Sallman DA
    Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
    Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
    Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
    Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
    Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
    Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
    Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in the 5q- Syndrome.
    Pellagatti A; Boultwood J
    Mediterr J Hematol Infect Dis; 2015; 7(1):e2015037. PubMed ID: 26075044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 20. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.